Related Experiment Video

Updated: Apr 7, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Developing and Using Therapeutics for Emerging Infections

Jeannine S McCune1, Kellie S Reynolds2

  • 1Department of Pharmacy, University of Washington, Seattle, Washington, USA.

Clinical Pharmacology and Therapeutics
|July 17, 2015
PubMed

Insights

Emerging infectious diseases like measles and Ebola highlight the need for new therapies and public education. Pharmacokinetic/dynamic modeling is crucial for combating infections, but adherence challenges and drug resistance remain significant concerns.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Outbreaks of vaccine-preventable diseases (e.g., measles) and emerging pathogens (e.g., Ebola) underscore global interconnectedness.
  • The rise of infectious diseases necessitates advancements in therapeutic development and public health strategies.

Discussion:

  • Pharmacokinetic/dynamic (PK/PD) modeling has been instrumental in managing infections like HIV and Hepatitis C.
  • Therapeutic adherence is critical; poor adherence contributes to the development of multidrug-resistant tuberculosis (MDR-TB).

Key Insights:

  • The journal issue covers preclinical models, PK/PD, pharmacogenomics, clinical trials, and educational efforts for emerging infections.
  • PK/PD modeling significantly reduces morbidity and mortality in viral infections.
  • Multidrug-resistant tuberculosis (MDR-TB) is a growing threat exacerbated by poor treatment adherence.

Outlook:

  • Continued research into novel therapies and robust public education are essential for managing future outbreaks.
  • Addressing adherence challenges is paramount to preserving the efficacy of antimicrobial therapies.
  • Lessons learned from past epidemics must inform strategies against re-emerging infectious threats.

More Related Videos

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

8.4K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.7K
Infection01:20

Infection

When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
14.4K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K